Compare Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN) vs QXO Inc. Common Stock (QXO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Haleon plc American Depositary Shares (Each representing two Ordinary Shares) vs QXO Inc. Common Stock — how do they compare? Haleon plc American Depositary Shares (Each representing two Ordinary Shares) trades at $9.89 (market cap $41.25B), while QXO Inc. Common Stock trades at $10.33 (market cap $11.43B). The key difference: Haleon plc American Depositary Shares (Each representing two Ordinary Shares) is far larger — about 3.6× QXO Inc. Common Stock's market cap, and Haleon plc American Depositary Shares (Each representing two Ordinary Shares) pays a 2.1% dividend while QXO Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Haleon plc American Depositary Shares (Each representing two Ordinary Shares) for 3 Days and QXO Inc. Common Stock for 0 Days on average.
| HLN | QXO | |
|---|---|---|
Market Cap | $41.25B | $11.43B |
Volume | 13,519,869 | 21,645,941 |
Sector | Health | Industrials |
52-Week High | $11.27 | $27.07 |
52-Week Low | $8.70 | $10.33 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $51.03B | $16.75B |
Dividend Yield | 2.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Haleon (HLN) trades at $9.44, down 0.63% today, with strong technical momentum showing a bullish moving average signal. The company demonstrates robust fundamentals with $11.03B revenue, 14.55% net margin, and consistent earnings beats in recent quarters. Recent business developments include successful shelf space negotiations with major retailers and growth from weight-loss drug side-effect products.
The outlook remains positive with 75% analyst buy ratings and improving cash flow projections for 2026. Key opportunities include market share gains and margin expansion, while risks involve competitive pressures and potential margin compression. The stock presents a balanced risk-reward profile for investors seeking exposure to consumer healthcare.
QXO trades at $11.02, up 3.57% on the day but down significantly year-to-date amid weak residential demand and integration challenges from its TopBuild acquisition. The stock shows neutral technical signals with support near $10-$11 and resistance at $12. Fundamentally, revenue grew to $6.84B in 2025 but net losses deepened to $279.4M, with a negative profit margin of -5.17% in 2026. Analyst sentiment remains bullish with a $22.89 consensus target, though recent news highlights margin pressure and execution risks.
The outlook hinges on successful integration of acquisitions and EBITDA growth targets, but high execution risk, negative earnings, and sector headwinds pose substantial downside. With 100% buy ratings from analysts and institutional accumulation, patient investors may see upside if management delivers on its playbook, though volatility is expected near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
Haleon is a consumer healthcare company offering over-the-counter medicines, oral health products, vitamins, and wellness brands.
Read more on HLN →About QXO Inc. Common Stock
QXO, Inc. is a distributor of roofing, insulation, waterproofing, and other building materials, serving contractors and builders across US and Canada through its network of branch locations.
Read more on QXO →
